RI
REGENXBIO Inc.
Organization
REGENXBIO Inc. is a clinical-stage biotechnology company focused on the development, commercialization, and licensing of recombinant adeno-associated virus (rAAV) gene therapy. The company utilizes its proprietary NAV Technology Platform to design and deliver curative gene therapies for diseases with significant unmet medical needs.
2 episodes featuring REGENXBIO Inc.
The Sunday Roast
Mining deals and biotech catalysts shape a midsummer market review
The episode tests how financing, clinical evidence, national resilience and exploration milestones could reshape several small-cap stories through 2026.
Aug 2, 2026 · 1h 45m
Stock Movers
AbbVie targets Apogee in eleven billion dollar deal as Regenxbio advances
Major pharmaceutical acquisitions and shifting regulatory pathways are rapidly redefining valuations in the biotechnology sector.
Jun 22, 2026 · 6 min